XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
Cell therapy stability studies are not shorter versions of biologics stability programs. They are fundamentally different studies — because cell therapy products degrade through biological processes that conventional stability science was not built to
View details →
Process validation for cell therapy is not impossible — it is just different. The FDA's 2011 guidance applies. But the way you design Stage 1, execute Stage 2, and monitor Stage 3 must reflect
View details → The analytical methods used to characterize and release cell therapy products are unlike any other in pharmaceutical science. Validating them to ICH Q2(R2) requires a cell-therapy-specific strategy that most standard method validation platforms cannot
View details → The QOS for a cell therapy product must summarize a drug that is, by definition, incompletely characterized. The way you handle that reality in Module 2.3 determines whether CBER trusts your entire CMC package.
View details → The cell therapy programs that reach BLA submission on schedule are not the ones that moved fastest in Phase 1. They are the ones that invested in CMC infrastructure while moving through Phase 1.
View details → A cell therapy CMC package built for CBER will satisfy many EMA requirements — and fail specific ones. Discovering which ones at pre-submission costs less than discovering them at Day 180 of a CAT
View details → A cell therapy BLA without a facility that passes inspection is a submission, not an approval. Understanding what CBER inspectors evaluate before you build or validate your facility is the only way to avoid
View details → The most successful cell therapy programs treat BLA approval not as the end of CMC work, but as the beginning of the manufacturing lifecycle where every change requires a regulatory strategy.
View details →
Breakthrough Therapy Designation does not accelerate FDA's CMC review standards. It accelerates the clinical program, compresses the development timeline, and brings the NDA filing date forward — often to a point where the CMC
View details → Every gene therapy lot that goes into a patient was released against a specification. Whether that specification can be defended at BLA — across all lots, all timepoints, all analytical method versions — is
View details → FDA's Accelerated Approval pathway has approved more than 250 drugs since 1992. The clinical story dominates the regulatory narrative. What almost never appears in that narrative is the CMC post-marketing commitment architecture — the
View details → A gene therapy stability program is not a stability program until it measures the right attributes at the right timepoints. Most early-stage GT stability programs measure the convenient attributes, not the critical ones.
View details → FDA formal meetings are among the most consequential strategic decisions in drug development, and most CMC teams use them incorrectly. Not because they fail to request them — Type B End-of-Phase 2 meetings are
View details → Lentiviral vectors integrate into the host genome. That single biological fact shapes every CMC expectation CBER has for your drug substance — from the design of your packaging system to your RCL testing strategy.
View details → A sponsor who walks out of a pre-NDA FDA meeting with confirmed minutes stating that their proposed bispecific antibody potency specification is acceptable has converted 60 minutes into regulatory protection against a deficiency letter.
View details → The Quality Overall Summary for a gene therapy product is the document CBER reviewers read first. It either demonstrates integrated CMC understanding or reveals the gaps before they open Module 3.
View details →
A Complete Response Letter with CMC deficiencies is not a list of things FDA wants you to add to your submission. It is a precisely worded document in which every deficiency represents a specific
View details → The FDA's 2011 Process Validation Guidance was written for the pharmaceutical industry. Applying it to a GT vector manufacturing process requires translation — and where that translation is missing, PPQ failures follow.
View details →